Protein-Ligand Co-crystallization Service

Protein-ligand co-crystallization is the definitive technique for visualizing how a small-molecule drug interacts with its target at atomic resolution. When applied to epigenetic targets, it provides the critical structural blueprint needed for rational inhibitor design. At CD BioSciences, we specialize in this precise challenge, offering an end-to-end co-crystallization service dedicated to transforming your epigenetic compounds into unambiguous structural insights that validate mechanisms, guide optimization, and accelerate discovery.

Overview of Protein-Ligand Co-crystallization

Protein-ligand co-crystallization is the process of forming and solving the three-dimensional atomic structure of an epigenetic target protein (e.g., a writer, reader, or eraser enzyme) in complex with a bound small-molecule ligand. This technique provides the definitive, high-resolution snapshot of the interaction, revealing the precise binding pose, key molecular contacts, and any ligand-induced conformational changes. For epigenetic drug discovery, this structural insight is transformative: it directly validates the mechanism of action, rationalizes structure-activity relationships (SAR) to guide lead optimization, explains selectivity profiles, and informs strategies to overcome drug resistance, thereby de-risking and accelerating the entire development pipeline.

Fig.1 Molecular dynamics simulations of DNMT1 in complex with compound ABACT19_57. Panel C illustrates prevalent protein-ligand interactions. (Prado-Romero D L, et al., 2024)

Our Services

At CD BioSciences, we specialize in protein-ligand co-crystallization services dedicated to advancing epigenetic drug discovery. Our focused expertise enables the structural elucidation of compound binding modes with key epigenetic targets, including histone-modifying enzymes, readers, and erasers. We deliver atomic-resolution insights to accelerate lead optimization and rational drug design.

Customized Solution for Protein-Ligand Co-crystallization Analysis

We specialize in obtaining high-resolution structural insights for compounds bound to notoriously difficult-to-express and hard-to-crystallize epigenetic targets. Our team brings proven expertise and a specialized toolkit to overcome these hurdles, delivering the atomic-level clarity needed to validate mechanisms and accelerate your lead optimization programs.

Workflow of Protein-Ligand Co-crystallization Service

Project Assessment & Design

In this initial phase, clients provide target information (including recommended protein constructs) and their ligand(s). Our expert scientists conduct a comprehensive feasibility assessment, leveraging our deep knowledge of epigenetic targets, and subsequently provide a detailed, customized experimental proposal to ensure project success.

Protein Expression & Purification

We employ optimized expression systems tailored for challenging epigenetic targets, such as insect or mammalian cell lines, to obtain properly modified and functional protein. This is followed by rigorous purification processes to deliver protein of high purity and homogeneity, which is a critical prerequisite for successful crystallization.

Complex Preparation & Crystallization Screening

The purified protein is incubated with the client's ligand to form a stable complex. We then utilize automated workstations to perform high-throughput, multi-dimensional crystallization screening. Our extensive condition libraries are strategically designed to address the specific properties of soluble epigenetic complexes, maximizing the chances of initial crystal hits.

Crystal Optimization & Data Collection

Any initial microcrystals are meticulously optimized through systematic refinement of conditions to grow large, diffraction-quality single crystals. High-resolution X-ray diffraction data is then collected at our partner synchrotron beamlines, ensuring the highest quality data for structure determination.

Structure Determination & Report Delivery

The phase problem is solved via molecular replacement or de novo modeling to determine the high-resolution co-crystal structure. We deliver the core results, including the refined electron density maps, a comprehensive binding mode analysis report highlighting key interactions (e.g., hydrogen bonds, hydrophobic contacts, π-π stacking), and the final coordinate file in PDB format.

Application Scenarios

Our co-crystallization service provides the critical structural insights needed to advance your epigenetic drug discovery program at key decision points:

1. Validating Novel Chemotype Binding Modes: Confirm the binding pose and mechanism of action of your unique scaffold, moving beyond predictive models to empirical truth.
2. Guiding Selectivity Optimization: Understand the structural basis for off-target interactions to rationally design compounds with improved selectivity profiles against closely related family members (e.g., within the BET or HDAC families).
3. Elucidating Resistance Mutations: Characterize how acquired mutations in epigenetic targets (e.g., EZH2, IDH1/2) alter the ligand-binding site, informing the design of next-generation compounds to overcome resistance.
4. Supporting Patent Applications & Publications: Secure robust intellectual property and publish high-impact research with definitive structural data that establishes the novelty and specific interactions of your therapeutic compounds.

Our Advantages

1. Deep Domain Expertise in Challenging Targets: Our team possesses specialized knowledge of the unique biochemical properties and structural complexities of epigenetic targets. This expertise allows us to anticipate and overcome common hurdles in expression, purification, and crystallization specific to writers, readers, erasers, and chromatin complexes.
2. Integrated Technology Platform for Reliable Delivery: We combine an advanced automated crystallization platform with a robust, optimized protein production workflow. This integrated approach ensures reproducible generation of high-quality protein and systematic screening, significantly increasing the success rate for even the most difficult targets.
3. Direct Access to High-Resolution Data Collection: Through established partnerships, we provide seamless access to high-flux synchrotron beamlines. This guarantees the collection of superior diffraction data, which is the critical foundation for solving high-resolution structures and obtaining unambiguous atomic-level insights.
4. End-to-End Project Execution with Single-Point Accountability: From construct design to structure analysis, we manage the entire co-crystallization pipeline. You benefit from a streamlined process, consistent communication, and a single team accountable for delivering the decisive structural data needed to guide your project's next steps.

The protein-ligand co-crystallization service is a cornerstone of our integrated structural biology platform at CD BioSciences. To provide a complete solution, we complement this with X-ray crystallography for apo-proteins, cryo-electron microscopy (Cryo-EM) for large complexes, and molecular dynamics simulations to bring static structures to life. This powerful combination delivers the precise insights you need, from initial hit validation to lead optimization. Contact us today to discuss how we can tailor this platform to de-risk and accelerate your specific epigenetic drug discovery program.

Reference

1. Prado-Romero D L, Saldívar-González F I, López-Mata I, et al. De novo design of inhibitors of DNA methyltransferase 1: A critical comparison of ligand-and structure-based approaches[J]. Biomolecules, 2024, 14(7): 775.